The employment of surgery as a single treatment modality for @entity1 with resectable locally advanced @entity213 ( @entity213 ) has been associated with high rates of locoregional recurrences even after adequate resection. The addition of postoperative radiotherapy (RT) as adjuvant to surgical resection for advanced @entity213 was investigated in an effort to decrease locoregional failure rates and improve treatment outcome. The unsatisfactory results in terms of locoregional control (LRC) and survival rates achieved with @entity86 in @entity1 with high-risk features have led to the necessity of exploring the role of concurrent chemotherapy in the adjuvant treatment in resectable advanced @entity213 with confirmed presence of high-risk pathological features. Two prospective randomized independent trials designed and conducted by Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of @entity5 (EORTC) demonstrated that the addition of @entity900 -based chemotherapy improved LRC and disease-free survival (DFS). Significant improvement in overall survival (OS) with the use of postoperative concurrent chemoradiotherapy (CCRT) was observed in the EORTC trial. High-risk pathological features in @entity1 with resected @entity135 representing adverse prognostic factors that are predictive for local and/or regional recurrence are related to the @entity5 and/or metastatic lymph nodes in the neck. Extracapsular extension (ECE) of @entity66 in the neck has been confirmed as a high-risk pathological feature negatively influencing LRC and survival in @entity1 treated with either @entity86 or postoperative CCRT. This article reviews the historical progress in the management of resectable locally advanced @entity213 and the impact of ECE on clinical outcome in @entity1 treated with adjuvant therapy following surgery. It can be concluded that strong evidence exists for an improved outcome for high-risk resected @entity1 treated with adjuvant CCRT. Precise definition of the presence of ECE is highly recommended in order to provide proper selection of @entity1 who would benefit from the postoperative CCRT.

Evolution of treatment and high-risk features in resectable locally advanced XXXX with special reference to extracapsular extension of @entity66 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck cancer'] @entity66 :: ('MESH:D004194', 'Disease') :: ['nodal disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['primary tumor', 'Cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative RT'] @entity213 :: ('MESH:C535575', 'Disease') :: ['head and neck squamous cell carcinoma', 'HNSCC']
@entity213 :: (MESH:C535575,Disease) :: ['Head and Neck squamous cell carcinoma']
